Table 3. Risk of obesity^a in end-stage kidney disease progression in participants undergoing kidney biopsies.

Kidney disease	Unadjusted			Adjustedb
	RR	95% CI	P	RR	95% CI	P
IgAN	1.29	0.92–1.79	0.140	1.49	1.01–2.20	0.045
FSGS	0.91	0.56–1.51	0.254	1.47	0.81–2.68	0.203
MCD	2.25	1.06–4.78	0.035	1.92	0.79–4.67	0.147
MN	1.81	0.81–3.74	0.112	1.92	0.75–4.92	0.172
DMN	0.82	0.51–1.31	0.411	1.06	0.63–1.79	0.819
LN	2.61	1.06–6.43	0.037	3.43	1.36–8.67	0.009
HT-N	0.89	0.31–2.54	0.829	0.85	0.24–3.05	0.801
MPGN	1.88	0.82–4.32	0.134	1.79	0.60–5.33	0.293

RR = relative risk, CI = confidence interval, IgAN = IgA nephropathy, FSGS = focal segmental glomerulosclerosis, MCD = minimal change disease, MN = membranous nephropathy, DMN = diabetic nephropathy, LN = lupus nephropathy, HT-N = hypertensive nephropathy, MPGN = membranoproliferative glomerulonephritis.

^aObesity was defined as body mass index ≥ 30 kg/m².

^bThe risks of kidney disease were adjusted by age, sex, systolic blood pressure, serum albumin, glucose, estimated glomerular filtration rate, hemoglobin, total cholesterol, cancer, and cardiovascular disease.